Kevin Shapiro
Neurology with Special Qualifications in Child Neurology · Madera, CANPI 1306006374
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,720 of the $84,439 with a category attached, or 99.1%. Novo Nordisk AS accounts for 99.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $33,661 and has fallen 99.7% since, to $106 in 2025. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $2723.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$84K
- Livanova USA, Inc.$162
- Jazz Pharmaceuticals Inc.$89
- Acadia Pharmaceuticals Inc$64
- Immedica Pharma US, Inc.$62
- Neurelis, Inc.$52
- plus $114 from 6 others
Across 56 payments — averaging $8747.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$483K
- Novo Nordisk$7K
What the payments were for
- Consulting fees$83,72099%
- Speaking & faculty fees$1740%
- Food & beverage$5431%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 11 | $83,894 |
| Livanova USA, Inc. | 2 | $162 |
| Jazz Pharmaceuticals Inc. | 4 | $89 |
| Acadia Pharmaceuticals Inc | 3 | $64 |
| Immedica Pharma US, Inc. | 2 | $62 |
| Neurelis, Inc. | 2 | $52 |
| Genentech USA, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NovoSeven RT$6,634
How this compares
$84,439 in reported general payments places this provider in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 14 | $2,286 |
| Cyclobenzaprine Hcl | 12 | $1,060 |
| Lorazepam | 17 | $406 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Madera
- Raymund DavidMadera$31K
- Cesar SantosMadera$16K
- Merveen AppuMadera$12K
- Giancarlo LugoMadera$10K
- Milagros Silva-ColonMadera$8K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.